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Dysplastic nevi (DN) is a strong risk factor for cutaneous malignant melanoma (CMM), and it frequently occurs in
melanoma-prone families. To identify genetic variants for DN, we genotyped 677 tagSNPs in 38 melanoma
candidate genes that are involved in pigmentation, DNA repair, cell cycle control, and melanocyte proliferation
pathways in a total of 504 individuals (310 with DN, 194 without DN) from 53 melanoma-prone families
(23 CDKN2A mutation positive and 30 negative). Conditional logistic regression, conditioning on families, was
used to estimate the association between DN and each single-nucleotide polymorphism (SNP) separately,
adjusted for age, sex, CMM, and CDKN2A status. P-values for SNPs in the same gene were combined to
yield gene-specific P-values. Two genes, CDK6 (cyclin-dependent kinase 6) and XRCC1, were significantly
associated with DN after Bonferroni correction for multiple testing (P¼ 0.0001 and 0.00025, respectively), whereas
neither gene was significantly associated with CMM. Associations for CDK6 SNPs were stronger in CDKN2A
mutation–positive families (rs2079147, Pinteraction¼ 0.0033), whereas XRCC1 SNPs had similar effects in mutation-
positive and -negative families. The association for one of the associated SNPs in XRCC1 (rs25487) was replicated
in two independent data sets (random-effect meta-analysis: Po0.0001). Our findings suggest that some
genetic variants may contribute to DN risk independently of their association with CMM in melanoma-
prone families.
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INTRODUCTION
Cutaneous malignant melanoma (CMM) is an etiologically
heterogeneous disease with genetic, host, and environmental
factors, and their interactions contributing to its development
(Tucker and Goldstein, 2003). Dysplastic nevi (DN) is a strong
risk factor for melanoma and occur frequently in melanoma-
prone families (Tucker et al., 2002). Previous studies have
suggested a genetic component for DN, but to date no
candidate genes have been identified. DN occurs with high
prevalence in high-risk melanoma–prone families with germ-
line mutations in CDKN2A, a major susceptibility gene for
CMM, suggesting that CDKN2A might confer risk for the
development of DN. However, there is a poor correlation
within families between CDKN2A gene-carrier status and DN
(Cannon-Albright et al., 1994; Hussussian et al., 1994; Bishop
et al., 2000). In addition, DN occurs in melanoma-prone
families with and without CDKN2A mutations with similar
frequency (Tucker et al., 2002). These findings suggest that
additional susceptibility genes or other genetic or epigenetic
mechanisms involving CDKN2A contributing to the
development of DN may exist in melanoma-prone families.
Identifying genetic variants for DN may enhance our
understanding of CMM susceptibility. Therefore, in this
study, we explored the associations between DN phenotype
and common genetic variants in 38 candidate genes selected
based on functional relevance in melanoma-prone families
with and without known CDKN2A mutations.
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RESULTS
A total of 677 tagSNPs in 38 melanoma candidate genes were
tested in 310 individuals with DN and 194 DN-unaffected
subjects (4 with CMM) from 53 melanoma-prone families with
and without CDKN2A mutations. The distribution of age,
gender, CDKN2A status, CMM, MC1R, pigmentation pheno-
type, and sun exposure variables are listed in Table 1. As
expected, age, CDKN2A, CMM, number of moles, tanning
ability, skin type, hair color, and MC1R were significantly
associated with DN in these families.
Age, gender, CDKN2A mutation status, and CMM status
were adjustment variables in all DN analyses. Table 2 shows
the six genes with gene-based P-value o0.05 for DN
associations. None of these genes were significantly asso-
ciated with CMM. Two genes, CDK6 (cyclin-dependent kinase
6) (P¼ 0.0001) and XRCC1 (P¼ 0.0003), were significantly
associated with DN after Bonferroni correction for multiple
testing (Table 2). Among genotyped single-nucleotide poly-
morphisms (SNPs) in these two genes, 4 out of 18 (none in
linkage disequilibrium (LD)) SNPs in CDK6 and 4 out of 13
(in 2 LD blocks) SNPs in XRCC1 had single SNP P-values
o0.05. Odds ratios (ORs) and 95% confidence intervals (CIs)
for the most significant SNPs in these two genes are shown in
Table 3. Further adjustment by pigmentation phenotypes (eye
color, hair color, skin type, and freckles), number of moles,
solar injury, and MC1R variants did not change the results
noticeably (data not shown). Analyses comparing DN cases to
unaffected family members and unrelated spouses separately
generated similar results (data not shown). In addition, as DN
may disappear with age, we further restricted our analyses to
subjects younger than 60 years old, and the associations were
similar (data not shown). To evaluate whether the associations
between these SNPs and DN were influenced by CMM status,
we restricted the analyses to CMM-unaffected subjects and
obtained similar results (Table 3).
To evaluate whether these genetic variants had similar
effects in families with and without CDKN2A mutations, we
analyzed the top four SNPs with P-values o0.05 in CDK6
and XRCC1, respectively, in CDKN2A mutation-positive
and -negative families separately. The associations between
XRCC1 SNPs and DN were similar in both sets of families
(Table 4). In contrast, the associations between CDK6 SNPs
and DN were observed in CDKN2A mutation–positive families
only (Po0.05 for all 4 SNPs), but not in mutation-negative
families (P40.2 for all 4 SNPs; Table 4). However, except for
rs2079147, which showed statistically significant interaction
with CDKN2A mutation status (P¼0.0033), effects for the
other three SNPs (rs1005346, rs2237570, and rs2285332)
were similar among CDKN2A-mutation carriers and non-
carriers in mutation-positive families (data not shown).
Two of the top four SNPs in CDK6 were also genotyped/
imputed in the two replication data sets, one consisting of 489
French probands and their relatives in a nevus family-based
study and the other consisting of 545 melanoma-unaffected
controls from three case–control studies of sporadic mela-
noma in Italy, but neither was significantly associated with
nevus count or DN in either data set (data not shown). Three
of the top four SNPs in XRCC1 were genotyped/imputed in
Table 1. Distribution of age, gender, CMM status,
CDKN2A status, MC1R, pigmentation phenotype, and
sun exposure variables in individuals with and without
DN from 53 families
Individuals
with DN
(N¼310)
Individuals
without DN
(N¼ 194)
P-value
N % N %
Age (years)
p30 88 28.4 12 6.2
30–40 75 24.2 38 19.6
40–50 72 23.2 71 36.6
50–60 43 13.9 53 27.3
60þ 32 10.3 20 10.3 o0.0001
Gender
Female 172 55.5 108 55.7
Male 138 44.5 86 44.3 0.97
CDKN2A
Non-carrier 196 64.3 172 90.5
Carrier 109 35.7 18 9.5 o0.0001
CMM
Unaffected 157 50.6 190 97.9
Case 153 49.4 4 2.1 o0.0001
Moles
0–24 15 4.9 94 49.7
25–99 101 33.1 80 42.3
100þ 189 62.0 15 7.9 o0.0001
Solar injury
None/mild 188 62.0 120 63.8
Moderate 74 24.4 40 21.3
Severe 41 13.5 28 14.9 0.69
Tanning ability
Tan/little burn 128 41.3 109 61.9
Burn/little tan 142 45.8 67 38.1 0.01
Skin type
Dark/medium 63 20.9 66 35.7
Pale/fair 239 79.1 119 64.3 0.0002
Eye color
Black/brown 60 19.8 56 30.3
Hazel 76 25.1 41 22.2
Green/gray 40 13.2 17 9.2
Blue 127 41.9 71 38.4 0.08
Hair color
Black/brown 120 39.6 97 53.0
Blonde brown/light brown 98 32.3 51 27.9
Blonde 44 14.5 23 12.6
Red 41 13.5 12 11.8 0.004
MC1R
Wild type 23 9.5 37 27.2
One non-synonymous variant 132 54.3 53 39.0
Two non-synonymous variants 88 36.2 46 33.8 o0.0001
Abbreviations: CMM, cutaneous malignant melanoma; DN, dysplastic
nevi.
P-values were obtained by comparing individuals with DN to unaffected
individuals using a generalized estimating equation and adjusting for
familial correlation in the variance.
X Liang et al.
Genetic Variants and Dysplastic Nevi
482 Journal of Investigative Dermatology (2014), Volume 134
each of the two replication data sets; among them, two were
genotyped/imputed in all three data sets (Table 5). The same
allele (allele C) in one SNP, rs25487, was significantly
associated with DN in the Italian study (P¼ 0.005) and
showed a borderline association with nevus count in the
French study (P¼0.084). This SNP showed a significant
association with DN/nevi (Po0.0001) in the meta-analysis
combining data from all three data sets. The most signifi-
cant SNP in the original data set, rs1001581 in XRCC1,
also showed a significant association (P¼ 0.0034) in the
meta-analysis, but this SNP is in strong LD (r240.8) with
rs25487.
DISCUSSION
DN is a strong risk factor for CMM and occurs often in CMM
high-risk families. Although previous studies suggested a
genetic component for DN, no genes for DN have been
identified yet. We systematically evaluated 38 candidate
genes in several biologically relevant pathways to identify
common genetic variants that are associated with DN in
melanoma-prone families with and without CDKN2A muta-
tions. We found that, two genes, CDK6 and XRCC1, were
significantly associated with DN susceptibility in our analyses.
XRCC1 is directly involved in the DNA base excision and
single-break repair pathways. A polymorphism of this gene,
rs25487 (Arg399Gln), has been associated with reduced
DNA repair capacity (Lunn et al., 1999; Duell et al., 2000).
However, its role in cancer susceptibility seems to be
complex. The same allele has been associated with both
increased and reduced risk depending on disease phenotype
and exposure (Karahalil et al., 2012). We observed a reduced
risk of DN associated with the T (Gln) allele, which was
observed in both replication data sets, and the P-value was
highly significant (Po0.0001) in our meta-analysis combining
all three data sets. Our results are in line with previous
findings that Arg399Gln was associated with a reduced risk
of non-melanoma skin cancers (Nelson et al., 2002) and a
reduced risk of metastasis in melanoma patients (Figl et al.,
2009). Our data suggest that this DNA repair pathway has an
important role in DN development. In addition, we found that
variants in XRCC1 were associated with DN, regardless of
CDKN2A mutation status.
CDK6 is a member of the CDK family. Taken together with
CDK4, CDK6 has an important role in G1-phase progression
Table 2. Genes associated with DN in melanoma
families with Po0.05
Gene-based P-values
Gene Chr. No. of SNP DN CMM
CDK6 7 18 0.0001 0.58
XRCC1 19 13 0.0003 0.61
EGFR 7 91 0.0086 0.09
CDKN1B 12 4 0.039 0.62
CCND3 6 1 0.045 0.7
APEX1 14 3 0.049 0.51
Abbreviations: CMM, cutaneous malignant melanoma; DN, dysplastic
nevi; SNP, single-nucleotide polymorphism.
P-values that remained significant after Bonferroni correction for multiple
testing are bolded.
Table 3. ORs for the most significant SNPs in CDK6 and XRCC1
SNP
DN unaffected DN affected Model 11 Model 22 Model 33
N % N % OR4 95% CI4 P-value4 OR4 95% CI4 P-value4 OR4 95% CI4 P-value4
CDK6
rs1005346
CC 88 45.1 176 56.2 Ref. Ref. Ref.
CT 82 42.1 122 39.0 0.44 0.24 0.80 0.0075 0.48 0.25 0.91 0.024 0.31 0.16 0.61 0.0007
TT 25 12.8 15 4.8 0.13 0.04 0.41 0.0006 0.14 0.04 0.47 0.0015 0.09 0.02 0.36 0.0007
P-trend 0.0002 0.0007 o0.0001
XRCC1
rs1001581
CC 62 31.8 126 40.3 Ref. Ref. Ref.
CT 99 50.8 149 47.6 0.49 0.26 0.90 0.021 0.51 0.27 0.97 0.039 0.44 0.23 0.85 0.015
TT 34 17.4 38 12.1 0.35 0.15 0.82 0.016 0.33 0.013 0.82 0.017 0.41 0.17 1.01 0.053
P-trend 0.0088 0.0094 0.027
Abbreviations: CI, confidence interval; CMM, cutaneous malignant melanoma; DN, dysplastic nevi; OR, odds ratio; SNP, single-nucleotide polymorphism.
1Model 1: age, gender, CMM, and CDKN2A adjustment.
2Model 2: age, gender, CMM, CDKN2A, solar injury, and MC1R adjustment.
3Model 3: restricted to CMM-unaffected subjects with age, gender, and CDKN2A adjustment.
4ORs and P-values are obtained from likelihood ratio test in conditional logistic regression, with DN as the outcome variable.
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by regulating the activity of the tumor suppressor protein
RB1 (Malumbres and Barbacid, 2009). Amplification and
overexpression of CDK6 have been reported in a variety of
cancers (Malumbres and Barbacid, 2009). CDKN2A is a
specific inhibitor for CDK4 and CDK6, and CDKN2A
residues that participate in contacting CDK4 or CDK6 are
mutated in tumors, including familial melanoma (Russo et al.,
1998). Given its obvious relevance, CDK6 has been
intensively studied as an important candidate high-
penetrance gene for familial melanoma, but disease-
cosegregating variants in this gene have not been identified.
In our study, we found that common genetic variants in CDK6
were significantly associated with DN, but not with CMM.
Interestingly, the association appeared to be restricted to
families with CDKN2A mutations. Our results are consistent
with findings from a previous genome-wide linkage scan for
DN in melanoma families segregating p16-Leiden mutations,
in which the strongest linkage signal for DN was mapped to
chromosome 7q21.3, a region containing CDK6 (de Snoo
et al., 2008). Given that the association was only seen in
Table 4. Associations of the most significant SNPs in CDK6 and XRCC1 with DN in CDKN2A-positive and -negative
families
CDKN2Aþ families CDKN2A families
SNP Ref. Var. OR* 95% CI* P-value* OR* 95% CI* P-value*
CDK6
rs1005346 C T 0.36 0.20, 0.63 0.0004 0.65 0.30, 1.42 0.28
rs2079147 G A 0.52 0.32, 0.87 0.0013 0.91 0.46, 1.77 0.77
rs2237570 A T 0.24 0.08, 0.71 0.0095 0.91 0.27, 3.04 0.88
rs2285332** G C 0.46 0.25, 0.85 0.014 1.17 0.57, 2.42 0.67
XRCC1
rs10015811 C T 0.64 0.39, 1.06 0.086 0.43 0.22, 0.84 0.0013
rs254871 C T 0.62 0.37, 1.03 0.064 0.46 0.24, 0.89 0.022
rs20236142 C G 2.48 1.04, 5.92 0.041 2.97 0.95, 9.32 0.062
rs9394612 A C 2.59 1.09, 6.13 0.031 2.43 0.85, 6.93 0.098
Abbreviations: CI, confidence interval; DN, dysplastic nevi; OR, odds ratio; SNP, single-nucleotide polymorphism.
*ORs and P-values are obtained from likelihood ratio test in conditional logistic regression with DN as the outcome variable and genotype analyzed as three-
level ordinal variable.
**This SNP showed significant interaction with CDKN2A mutation status (P¼0.0033).
1,2These two SNPs are in linkage disequilibrium (r240.8).
Table 5. XRCC1 SNPs in three independent data sets
SNP
NCI test1 Italian2 French3 Combined4
OR Lower Upper P-value OR Lower Upper P-value OR Lower Upper P-value OR Lower Upper P-value
rs25487 0.57 0.37 0.87 0.0093 0.51 0.32 0.81 0.005 0.69 0.45 1.05 0.084 0.59 0.46 0.76 o0.0001
rs2023614 2.74 1.32 5.67 0.0067 0.91 0.47 1.79 0.79 1.56 0.53 4.61 0.425
rs1001581 0.57 0.37 0.87 0.0088 0.70 0.45 1.08 0.10 0.63 0.46 0.86 0.0034
rs939461 2.53 1.25 5.11 0.0095 0.94 0.45 1.97 0.87 1.06 0.57 1.98 0.84 1.35 0.75 2.46 0.32
Abbreviations: CMM, cutaneous malignant melanoma; DN, dysplastic nevi; LD, linkage disequilibrium; OR, odds ratio; SNP, single-nucleotide polymorphism.
1ORs and P-values are obtained from likelihood ratio test in conditional logistic regression with DN as the outcome variable and genotype analyzed as three-
level ordinal variable, with the adjustment of age, gender, CMM, and CDKN2A status.
2ORs and P-values are obtained from unconditional logistic regression models with DN as a binary variable (presence vs. absence) and the adjustment of age
and gender. The analysis was restricted to CMM-unaffected subjects.
3ORs and P-values are obtained by comparing the extremes of the distribution of the sex- and age-adjusted log-transformed nevus density. The analysis used
unconditional logistic regression and the allele dosage to take into account the uncertainty of imputed genotypes with robust sandwich estimation of the
variance as implemented in the Stata logit function to model clustering of family genotypes. The analysis was restricted to CMM-unaffected subjects.
4Meta-analysis was conducted using random-effect model to combine SNP effects across different data sets.
5P-value for heterogeneity was significant for this SNP (P¼ 0.03).
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CDKN2A mutation–positive families, it is not surprising that
we did not replicate the association in other data sets that
mostly included subjects negative for CDKN2A mutations.
However, although the association was driven by mutation-
positive families, most SNPs, including the most significant
SNP (rs1005346), showed significant associations even among
CDKN2A-negative subjects with DN in mutation-positive
families. Our data suggest that other variants in the cell cycle
control pathway, in addition to CDKN2A mutations, may
contribute to DN susceptibility in these families.
None of the DN-associated SNPs in XRCC1 and CDK6 was
significantly associated with CMM risk. Although DN is a
strong risk factor for CMM, the majority of individuals affected
with DN do not develop melanoma. In addition, DN lesions
rarely transform to melanoma, suggesting that additional
genetic and/or environmental factors may determine the
development of CMM from DN. However, it is also possible
that these variants might be associated with CMM, but our
analyses had limited power in identifying the significance
because of the smaller number of CMM cases (N¼157) than
DN cases (N¼310). In addition, we adjusted CMM in all
models in the NCI data set and restricted to CMM-unaffected
people in the two replication data sets; therefore, our analyses
were more likely to identify DN-specific variants. Further,
individuals affected with DN, particularly in CMM high-risk
families, may be more self-educated in using sun protection,
which could disrupt the natural history of CMM development.
Indeed, although none of the DN-associated SNPs was
significantly associated with CMM, the directions of the
associations with DN and CMM were the same.
The strengths of our study include a rich collection of
genetic, environmental, clinical, and pigmentation data in
DN-enriched melanoma-prone families with and without
CDKN2A mutations. In addition, we used data from two
independent data sets to replicate our findings. Our study also
has limitations. We included CMM cases in our analyses,
which could potentially cause bias in DN association ana-
lyses. However, when we restricted the analyses to CMM-
unaffected individuals for the most significant SNPs, we
observed similar associations with DN. In addition, analyses
were restricted to CMM-unaffected people in the two replica-
tion data sets. We also conducted sensitivity analyses by
analyzing DN-unaffected family members and spouses sepa-
rately as controls and the results were similar to those using
the combined control group. Another limitation was that our
families were ascertained primarily through self- or physician
referral, and thus findings may not be generalizable to the
general population.
In summary, we found that genetic variants in XRCC1 were
associated with DN susceptibility, a result that was replicated
in two independent data sets. Future studies are needed to
identify functional variants in XRCC1 that influence expression
levels of the gene and DNA repair efficiency in DN samples.
In addition to XRCC1, we found that variants in CDK6 were
associated with DN in families with CDKN2A mutations,
which is consistent with a previous report of linkage in the
CDK6 region for DN in melanoma families with p16-Leiden
mutations (de Snoo et al., 2008). Our data suggest that genetic
variants may confer DN susceptibility that is independent of
CMM risk in melanoma-prone families. Future evaluations of
these genes in relation to DN in melanoma families and in the
general population are needed to confirm these findings.
MATERIALS AND METHODS
Study population
American melanoma-prone families with at least two living first-
degree relatives with a history of invasive CMM were ascertained
through health-care professionals or self-referrals. Details of our
familial melanoma patients were described previously (Goldstein
et al., 2000, 2005). Briefly, all family members willing to participate
in the study underwent a full-body skin examination and completed
risk factor questionnaires for sun-related exposures. All diagnoses
of melanoma were confirmed by histological review of pathologic
material, pathology reports, or death certificates. To be defined as
dysplastic, a nevus had to be 5 mm or larger in at least one
dimension, have a flat component, and meet at least two of the
following criteria: variable pigmentation, indistinct borders, and
irregular outline. The study was approved by the National Cancer
Institute Clinical Center Institutional Review Board and was
conducted according to the Declaration of Helsinki Principles. All
subjects gave written informed consent. Data from this study came
from 53 families (23 families with CDKN2A mutations and 30
families without known mutations; Table 1). All CMM and DN cases
with DNA available were selected. Controls included DN-unaffected
family members and unrelated spouses. Only adult controls were
selected to minimize disease misclassification. All study participants
were Caucasian.
Gene and SNP selection and genotyping
A total of 38 candidate genes were selected based on their reported
involvement in melanoma and functional relevance (cell cycle
control (CCNA1, CCND1, CCND2, CCND3, CCNE1, CDK2,
CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C,
ING1, ING2), pigmentation (ASIP, OCA2, SLC24A2, SLC24A5,
TYRP1, TYRP2, EDNRB, EGFR, PPARD, DRD2), DNA repair (ERCC1,
ERCC4, XRCC3, XRCC1, APEX1, ERCC2, XPC, ERCC5, MGMT,
VDR), and melanocyte proliferation (BRAF, MITF, KITLG),
Supplementary Table 1 online). TagSNPs were chosen from the set
of available common SNPs using the program Tagzilla (http://tagzilla.
nci.gov), which has been described elsewhere (Liang et al., 2011).
Briefly, for each originally targeted gene, SNPs within the region
spanning 20 kb 50 end of the start of transcription (exon 1) to 10 kb 30
end of the last exon were grouped using a binning threshold of
r240.8 to define a gene/region. When there were multiple transcripts
available for genes, only the primary transcript was assessed. The
selected tagSNPs had a minor allele frequency 45% and r2o0.8
based on Caucasian and Yoruban population samples of the
HapMap project (Data Release 20/Phase II, NCBI Build 36.1
assembly, dbSNP b126). Genotyping of tagSNPs was conducted at
the NCI Core Genotyping Facility (Advanced Technology Center,
Gaithersburg, MD; http://snp500cancer.nci.nih.gov) using a custom-
designed iSelect Infinium assay (Illumina, www.illumina.com).
Quality control
The SNPs with low (o90%) genotyping completion rate, low (o90%)
concordance rate with the three HapMap population (Caucasian,
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Yoruban, Japan, and China) samples, or deviation (Po0.001) from
Hardy–Weinberg equilibrium among founders were excluded.
Among 586 genotyped samples, 20 were excluded because of low
completion (o90%, n¼ 12) and Mendelian inconsistencies (n¼ 8).
Sixty-two individuals were further removed from DN analyses
because of missing CMM status (n¼ 4) or undetermined DN status
(n¼ 58).
Replication data sets
We used two independent data sets to replicate the associations we
found in our original data set. The detailed description of the two
replication data sets is presented in Supplementary Material online.
Briefly, the first data set was derived from a nevus family-based study
conducted in France including 220 families ascertained through
probands who had a high number of nevi (X 50 nevi) and no
melanoma at the time of recruitment into the study; genome-wide
genotyping was performed for 489 probands and their relatives
(siblings for the most part) using Illumina Humancnv370k array and
Illumina Human660W-Quad BeadChip (San Diego, CA). To combine
the SNP data generated from these two arrays, genotypic imputations
were performed in each of the genotyped data sets separately using
the Hapmap3 reference panel and the MACH software (Li et al.,
2010). Stringent quality control criteria were applied to both geno-
typed subjects before imputations and imputed SNPs (imputation
quality score r2X0.80 and minor allele frequency X0.05). There
were 473 subjects who passed QC, and 429 of them had whole-body
nevi counts available.
The second replication data set included controls from three case–
control studies of sporadic melanoma. Briefly, in the first case–control
study (Landi et al., 2001, 2005), cases were incident sporadic
melanoma patients diagnosed at the Dermatology Unit of Maurizio
Bufalini Hospital in Cesena, Northern Italy. Controls were spouses or
friends of the cases, patients treated at the same hospital for minor
accidental trauma, or healthy hospital personnel recruited during the
same period without a history of melanoma and coming from the
same geographical areas as the cases. A single dermatologist (DC)
performed skin examinations for all study subjects to determine
pigmentation characteristics including nevi and DN. A total of 173
controls with blood samples were included in this study. In the
second study (Fargnoli et al., 2006), sporadic melanoma patients
were diagnosed at the Departments of Dermatology of the
Universities of L’Aquila, Florence, or Modena in central Italy.
Subjects treated for diseases unrelated to melanoma at the Surgery
and Internal Medicine Departments of the corresponding Universities
were recruited as controls for the study. Clinical examination of all
subjects was performed by two dermatologists (KP and MCF). A total
of 165 controls with blood samples were included in this study. The
third case–control study was of sporadic melanoma cases diagnosed
at the units of dermatology, medical oncology, and plastic surgery of
the National Cancer Research Institute and San Martino Hospital,
Genoa, in Northern Italy (Ghiorzo et al., 2012). Similarly, subjects
without a history of melanoma, and who were older than 18 years of
age were recruited at the same hospital during the same period as
controls. A total of 207 controls with blood samples were included in
this study.
All studies in the replication data sets were approved by the local
and NCI Institutional Review Boards, and all subjects signed an
informed consent form.
Statistical analysis
For each SNP we calculated the Ptrend based on the three-level ordinal
genotype variable (0, 1, 2) that counted the number of minor alleles in
conditional logistic regression models for the association with DN,
conditioning on family to account for the ascertainment. Although
this approach ignores residual correlation among family members,
it gives estimates that are attenuated toward the null and thus is
considered conservative (Pfeiffer et al., 2001). We calculated ORs
and 95% CIs for each genotype using the homozygous common
allele genotype as the referent group. When the number of subjects
with homozygous minor alleles was o5, heterozygote and
homozygote minor allele genotypes were combined. All regression
models were adjusted for age, gender, CMM status, and individual
CDKN2A mutation status. For the most significant SNPs in XRCC1
and CDK6, we further adjusted for solar injury and MC1R as a
surrogate for pigmentation characteristics. Most pigmentation risk
phenotypes, such as red hair color, poor tanning ability, pale/fair
skin color, and extensive freckling, were previously associated
with MC1R variants in our CDKN2A mutation–positive families
(Goldstein et al., 2005). MC1R variants were coded as 0¼ no
variant, 1¼ single variant, and 2¼multiple variants. We also
analyzed the most significant SNPs in CDKN2A mutation-positive
and -negative families separately to assess effects modified by
mutation status in families.
The primary aim of our study was to identify candidate genes
associated with DN risk. Gene-based P-values for association were
obtained by combining SNP-based P-values for trend using rank-
truncated test statistics (Dudbridge and Koeleman, 2003) and a
permutation-based sampling procedure (20,000 permutations),
which takes into account the number of SNPs genotyped in each
gene and their LD structure. Age, gender, CMM status, and CDKN2A
mutation status were included in all conditional regression models.
To adjust for multiple gene comparisons, we applied the Bonferroni
correction method and considered gene-based P-values o0.0013
(0.05/38) to be statistically significant. All analyses were conducted
using SAS version 9.3 (SAS Institute, Cary, NC).
Analyses for both replication data sets were restricted to CMM-
unaffected individuals. In the French data set, the nevus density
(nevus count divided by body surface) was used because DNs were
not recorded with sufficient accuracy. In addition, DN and nevus
count are known to be strongly correlated (Tucker et al., 1997). The
association analyses were conducted by comparing those with
extremely high values of the sex- and age-adjusted log–transformed
nevus density (above the 75th percentile, n¼ 108) to those with
extremely low values of nevus density (lower than the 25th percentile,
n¼ 107). The analysis used unconditional logistic regression and
the allele dosage to take into account the uncertainty of imputed
genotypes with robust sandwich estimation of the variance
as implemented in the Stata logit function to model clustering of
family genotypes (Williams, 2000); the type of genotyping chip
was included as a covariate in the model. The analysis was also
repeated by using the age- and sex-adjusted log-nevus density as
a quantitative phenotype, and similar results were obtained. In
the Italian study, unconditional logistic regression models
were used to analyze DN as a binary variable (presence vs.
absence), adjusted for age and gender. We used a random-
effect meta-analysis to combine SNP effects across different
data sets.
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